These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 35851868)

  • 1. Infigratinib for cholangiocarcinoma.
    Sadeghi S
    Drugs Today (Barc); 2022 Jul; 58(7):327-334. PubMed ID: 35851868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infigratinib in patients with advanced cholangiocarcinoma with
    Makawita S; K Abou-Alfa G; Roychowdhury S; Sadeghi S; Borbath I; Goyal L; Cohn A; Lamarca A; Oh DY; Macarulla T; T Shroff R; Howland M; Li A; Cho T; Pande A; Javle M
    Future Oncol; 2020 Oct; 16(30):2375-2384. PubMed ID: 32580579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
    Frampton JE
    Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
    Krook MA; Lenyo A; Wilberding M; Barker H; Dantuono M; Bailey KM; Chen HZ; Reeser JW; Wing MR; Miya J; Samorodnitsky E; Smith AM; Dao T; Martin DM; Ciombor KK; Hays J; Freud AG; Roychowdhury S
    Mol Cancer Ther; 2020 Mar; 19(3):847-857. PubMed ID: 31911531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements.
    White K; Anwar AI; Jin K; Bollich V; Kelkar RA; Talbot NC; Klapper RJ; Ahmadzadeh S; Viswanath O; Varrassi G; Shekoohi S; Kaye AD
    Cureus; 2023 Oct; 15(10):e46792. PubMed ID: 37954763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
    Javle M; Roychowdhury S; Kelley RK; Sadeghi S; Macarulla T; Weiss KH; Waldschmidt DT; Goyal L; Borbath I; El-Khoueiry A; Borad MJ; Yong WP; Philip PA; Bitzer M; Tanasanvimon S; Li A; Pande A; Soifer HS; Shepherd SP; Moran S; Zhu AX; Bekaii-Saab TS; Abou-Alfa GK
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):803-815. PubMed ID: 34358484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.
    Botrus G; Raman P; Oliver T; Bekaii-Saab T
    Expert Opin Investig Drugs; 2021 Apr; 30(4):309-316. PubMed ID: 33307867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
    Chakrabarti S; Finnes HD; Mahipal A
    Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infigratinib: First Approval.
    Kang C
    Drugs; 2021 Jul; 81(11):1355-1360. PubMed ID: 34279850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
    Rizzo A
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infigratinib in pretreated cholangiocarcinoma with FGFR2 fusions or rearrangements.
    Neuzillet C
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):773-775. PubMed ID: 34358483
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
    Ang C
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1116-22. PubMed ID: 25678238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Futibatinib for cholangiocarcinomas with a FGFR2 fusion or rearrangement, locally advanced or metastatic].
    Noé C; Edeline J
    Bull Cancer; 2023 Oct; 110(10):985-986. PubMed ID: 37500387
    [No Abstract]   [Full Text] [Related]  

  • 15. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
    Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
    Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
    Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
    J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
    Patel TH; Marcus L; Horiba MN; Donoghue M; Chatterjee S; Mishra-Kalyani PS; Schuck RN; Li Y; Zhang X; Fourie Zirkelbach J; Charlab R; Liu J; Yang Y; Lemery SJ; Pazdur R; Theoret MR; Fashoyin-Aje LA
    Clin Cancer Res; 2023 Mar; 29(5):838-842. PubMed ID: 36206041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
    Uson PLS; Bearss J; Babiker HM; Borad M
    Expert Opin Drug Saf; 2023; 22(8):637-641. PubMed ID: 37363820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
    Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond.
    Uson Junior PLS; Borad MJ
    Expert Opin Investig Drugs; 2022 Jan; 31(1):125-131. PubMed ID: 34904492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.